Welcome to our dedicated page for Transmedics Group news (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on Transmedics Group stock.
TransMedics Group, Inc. (Nasdaq: TMDX) is a medical technology company that focuses on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. News about TransMedics often centers on its Organ Care System (OCS) warm perfusion platform, the National OCS Program (NOP), and initiatives aimed at increasing donor organ utilization.
Investors and healthcare professionals following TransMedics news can expect updates on financial results, including quarterly earnings announcements and related conference calls, as reflected in the company’s regular press releases and Form 8-K filings. Coverage also includes participation in major healthcare and investor conferences, where management presents the company’s strategy and discusses its transplant-focused technologies and services.
Another key news theme is TransMedics’ expansion of its logistics and service infrastructure. The company has disclosed the acquisition of fixed-wing aircraft for its National OCS Program and has announced a strategic collaboration with Mercedes-Benz Group AG to launch a dedicated organ transplantation ground transportation network in Italy using Mercedes-Benz V-Class vehicles. These developments are presented as part of a broader effort to build an integrated air and ground logistics network around the OCS platform.
TransMedics also issues news related to corporate growth, such as inducement equity grants under Nasdaq Listing Rule 5635(c)(4) and plans for a new global headquarters and integrated campus in Somerville, Massachusetts. For readers tracking TMDX, this news feed provides a centralized view of operational updates, regulatory and financial disclosures referenced in press releases, and developments in the company’s organ transplant technologies and services.
TransMedics Group, Inc. (TMDX) reported third-quarter 2020 net revenue of $7.1 million, a 2% decrease from Q3 2019. The decline was primarily due to the ongoing effects of the COVID-19 pandemic. Gross margin improved to 71% from 59% year-over-year, while operating expenses decreased to $9.6 million from $11.5 million. The net loss for the quarter was $5.1 million, a reduction from $8.3 million in the same period last year. Cash reserves stood at $132.7 million as of September 30, 2020.
TransMedics Group, Inc. (NASDAQ: TMDX) announced its participation in two virtual investor conferences. The management team will attend the Oppenheimer Fall MedTech Summit on November 12, 2020, and the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020. These events will consist of 1x1 meetings only, with no webcasts available. TransMedics is a leader in portable extracorporeal warm perfusion for organ transplantation, focusing on enhancing organ quality and viability for patients with end-stage organ failure.
TransMedics Group, Inc. (TMDX) will release its third-quarter financial results on November 4, 2020, after market close. Following this, a conference call will be held at 4:30 p.m. ET. Investors can access the call by dialing (833) 378-1026 domestically or (236) 712-2500 internationally, using Conference ID: 1716957. TransMedics is a leader in organ transplant technologies, focusing on enhancing organ quality and increasing the utilization of donor organs for patients with end-stage organ failure.
TransMedics Group announced that the FDA has postponed the Advisory Committee meeting originally set for October 7, 2020, to review its OCS Heart premarket approval application. This delay allows the FDA to evaluate additional data from the OCS Heart EXPAND trial and its Continued Access Protocol. Despite the setback, TransMedics remains confident in the trial results supporting the OCS Heart’s approval to aid heart transplant patients in the U.S.
TransMedics Group, Inc. (Nasdaq: TMDX) announced the FDA's postponement of the Advisory Committee meeting regarding its OCS Heart premarket approval application, originally set for October 7, 2020. The delay allows the FDA to review additional data from the OCS Heart EXPAND trial. CEO Waleed Hassanein expressed disappointment but remains confident that the results will support FDA approval. The company specializes in portable organ preservation technologies aimed at enhancing organ transplantation outcomes.
TransMedics Group, Inc. (TMDX) reported a 40% decline in net revenue for Q2 2020, totaling $3.4 million compared to $5.7 million in Q2 2019, largely due to reduced organ transplant procedures amid the COVID-19 pandemic. The gross margin decreased to 56% from 59% year-over-year. Despite a net loss of $8.5 million, down from $9.2 million in the previous year, the company successfully raised $75 million in a public equity offering. TransMedics remains focused on advancing its OCS product initiatives with expected FDA approvals in 2021.
TransMedics Group, Inc. (Nasdaq: TMDX), a leader in organ transplant technology, will present at the Canaccord 40th Annual Growth Conference on August 13, 2020, at 10:00 a.m. EDT. This virtual event aims to highlight their innovations in portable organ preservation and assessment, which are critical for improving transplantation outcomes for patients with end-stage heart, lung, and liver failure. A live and archived webcast will be available on their website.
TransMedics Group, Inc. (TMDX) has announced that it will release its second-quarter financial results on August 5, 2020, after market close. The management team will host a conference call at 4:30 p.m. ET to discuss the results. Investors can join the call by dialing specific numbers for domestic and international callers. TransMedics specializes in portable extracorporeal warm perfusion technology, which improves organ transplant therapy for patients with end-stage organ failure.
TransMedics Group, Inc. (Nasdaq: TMDX) has announced a public offering of 5,000,000 shares of common stock at $14.00 per share, aiming for gross proceeds of $70 million. The offering is anticipated to close on May 29, 2020, subject to customary conditions. An additional 750,000 shares may be purchased by underwriters within 30 days. J.P. Morgan and Morgan Stanley lead the offering, with SEC registration effective since May 21, 2020. This initiative supports TransMedics' mission to enhance organ transplant therapies.
TransMedics Group, Inc. (TMDX) announced a public offering of $60 million in common stock, with J.P. Morgan and Morgan Stanley as joint lead managers. The offering may include an additional 15% to be purchased by underwriters. The effective shelf registration statement was filed with the SEC on May 21, 2020. This offering aims to enhance the company's capabilities in organ transplant technologies, addressing the need for improved organ preservation and viability assessment. Investors are cautioned regarding potential risks that may affect the offering's completion.